Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2001 4
2002 2
2003 1
2004 1
2005 4
2006 3
2007 3
2008 6
2009 4
2010 2
2011 3
2012 5
2013 3
2014 5
2015 3
2016 1
2017 2
2018 1
2019 2
2020 3
2021 5
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa study.
Rikken SAOF, Bor WL, Selvarajah A, Zheng KL, Hack AP, Gibson CM, Granger CB, Bentur OS, Coller BS, van 't Hof AWJ, Ten Berg JM. Rikken SAOF, et al. Am Heart J. 2023 Aug;262:75-82. doi: 10.1016/j.ahj.2023.04.009. Epub 2023 Apr 22. Am Heart J. 2023. PMID: 37088164 Free PMC article. Clinical Trial.
Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction.
Bor WL, Zheng KL, Tavenier AH, Gibson CM, Granger CB, Bentur O, Lobatto R, Postma S, Coller BS, van 't Hof AWJ, Ten Berg JM. Bor WL, et al. EuroIntervention. 2021 Aug 6;17(5):e401-e410. doi: 10.4244/EIJ-D-21-00287. EuroIntervention. 2021. PMID: 34031019 Free PMC article. Clinical Trial.
First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction.
Kereiakes DJ, Henry TD, DeMaria AN, Bentur O, Carlson M, Seng Yue C, Martin LH, Midkiff J, Mueller M, Meek T, Garza D, Gibson CM, Coller BS. Kereiakes DJ, et al. J Am Heart Assoc. 2020 Sep;9(17):e016552. doi: 10.1161/JAHA.120.016552. Epub 2020 Aug 26. J Am Heart Assoc. 2020. PMID: 32844723 Free PMC article. Clinical Trial.
64 results